Indaptus Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Indaptus Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.98M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.23M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($5.23M) | Nov 12, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($4.53M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.53M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($4.53M) | Nov 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.07M) | Nov 12, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($4.02M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.02M) | Aug 13, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.81M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.81M) | May 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.81M) | Nov 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($3.92M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.25M) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($3.25M) | Nov 12, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($4.25M) | Nov 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.25M) | May 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($4.25M) | Aug 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.47M) | Nov 6, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($3.84M) | Nov 6, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.65M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.46M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($4.57M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.14M) | Nov 12, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($4.11M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.94M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($4.25M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($3.50M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($4.46M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($3.55M) | Nov 6, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($3.87M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($3.40M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($3.37M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($528.6K) | Aug 8, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($614.0K) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($1.55M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($2.91M) | Aug 16, 2021 |